Early Flow Diversion Shows Exceptional Promise for Ruptured Blister Aneurysm Treatment

Could Early Flow Diversion Revolutionize Blister Aneurysm Management?

Early flow diversion has emerged as a promising vessel-preserving approach for the management of ruptured intracranial blister aneurysms, according to a recent retrospective analysis conducted at Gleneagles Hospital in Mumbai, India. The study, which followed 21 patients over a period ranging from February 2017 to December 2022, provides valuable insights into the efficacy and safety of flow diverter devices (FDDs) when deployed within the critical first 72 hours following subarachnoid hemorrhage (SAH). Blister aneurysms represent a particularly challenging subset of intracranial vascular pathology, characterized by their thin, fragile walls and negligible necks. These rare lesions constitute approximately 0.9-6.5% of internal carotid artery lesions and fewer than 2% of all intracranial aneurysms, yet they carry a disproportionately high risk of rupture, regrowth, and treatment complications compared to their saccular counterparts. The hemispheric, broad morphology of these lesions, combined with their tendency to arise from non-branching arterial segments and undergo erratic morphological changes, creates significant management challenges for neurovascular specialists, particularly in the acute setting following rupture. The etiology of these lesions remains multifactorial, with atherosclerosis, hemodynamic stress related to hypertension, and arterial dissection creating pseudoaneurysms all proposed as potential mechanisms in their pathogenesis. The propensity of these lesions to rapidly change in size and morphology, sometimes within days of presentation, underscores the urgency of definitive management to prevent catastrophic rebleeding.

The management of blister aneurysms has historically been challenging, with various reconstructive and deconstructive techniques described in the literature. Reconstructive approaches include both surgical options (direct suturing, wrapping, clip-wrapping, wrap-clipping, and primary clipping) and endovascular techniques (primary coiling, telescopic stenting, stent-assisted/balloon-assisted coiling, and flow diversion). Deconstructive approaches involve parent artery occlusion, with or without bypass procedures. Among the endovascular approaches, flow diversion has shown particularly promising results, though literature on its application in the acute ruptured setting remains limited, especially in developing countries where diagnosis and intervention might face delays. The study cohort consisted predominantly of patients with lower-grade subarachnoid hemorrhage (Hunt and Hess grades I-III), with a mean age of 58 years and a slight female preponderance (57%). Comorbidities were common, with hypertension present in 13 patients (six on irregular therapy), type II diabetes in 11 patients, and dyslipidemia also frequently observed. Notably, 42.8% of cases demonstrated coexistent atherosclerotic vessel wall irregularity on initial digital subtraction angiography (DSA), potentially contributing to the pathogenesis of these lesions. The majority of blister aneurysms (17/21) were located at the supraclinoid internal carotid artery (ICA), with the remainder found at the basilar trunk (3/21) and anterior communicating artery (1/21).

Is Strategic Early Intervention the Key to Success?

The investigators employed a standardized protocol for patient evaluation and management. Upon admission, patients underwent comprehensive neurological assessment using established grading systems including the Hunt and Hess scale, World Federation of Neurosurgical Societies (WFNS) hemorrhage scale, and modified Fisher grading. Imaging studies included non-contrast computed tomography (CT), CT angiography (CTA), magnetic resonance angiography (MRA), and digital subtraction angiography (DSA) with three-dimensional rotational capabilities to accurately characterize aneurysm morphology and plan treatment strategies. The timing of intervention was particularly noteworthy, with eight patients undergoing treatment on day 1 following SAH onset, seven on day 2, and six on day 3. This early intervention approach was deliberately chosen to mitigate the risk of rebleeding, which is particularly high with blister aneurysms due to their fragile nature. All patients received a standardized antiplatelet and anticoagulation protocol, consisting of systemic heparinization during the procedure (5,000 IU intra-arterial bolus initially, followed by 1,000 IU intravenous boluses hourly) and loading doses of dual antiplatelet agents (ticagrelor 180 mg and aspirin 75 mg) administered at anesthesia induction. This aggressive antithrombotic regimen was deemed necessary despite the theoretical increased risk of hemorrhagic complications in the setting of acute SAH, reflecting the investigators' assessment that the risk of thromboembolic complications without adequate antiplatelet coverage outweighed the bleeding risk with dual antiplatelet therapy (DAPT).

The technical aspects of the endovascular procedures were meticulously documented. Various flow diverter devices were utilized, including the Pipeline™ Embolisation Device (PED) in four cases, the DERIVO® 2heal® Embolisation Device in 14 cases, and the Silk Vista Flow Diverter in three cases. All procedures were performed under general anesthesia via a transfemoral approach, utilizing a tri-axial system consisting of a microcatheter, intermediate or distal access catheter, and long sheath. The size selection strategy involved oversizing the FDD by approximately 0.5 mm relative to the proximal landing zone diameter. Notably, no adjunctive coiling was performed in any case, representing a pure flow diversion approach. The primary outcome measure was complete angiographic obliteration of the aneurysm at 6-12 months follow-up, with secondary outcomes including immediate procedural stasis, clinical outcomes measured by the modified Rankin Scale (mRS), and procedure-related complications. The investigators observed immediate contrast stasis (15 minutes post-deployment) in 85.7% of cases (18/21), with immediate complete aneurysm obliteration evident in 42.8% (9/21) of patients. Two patients (9.5%) developed intraluminal thrombus following FDD deployment, necessitating rescue therapy with tirofiban. At angiographic follow-up (6 months), complete aneurysm obliteration was documented in 90.5% of cases (19/21), with the remaining two patients showing partial obliteration at both 6-month and 1-year follow-up assessments.

How Might These Findings Shape Future Clinical Practice?

Perhaps most importantly from a clinical perspective, all patients achieved favorable outcomes (mRS 0-2) at final follow-up, with no cases of perioperative mortality, rebleeding, thromboembolic complications, severe vasospasm, or hydrocephalus requiring cerebrospinal fluid diversion. The investigators specifically noted their preference for ticagrelor over clopidogrel in the acute setting, citing the high prevalence of CYP2C19 genetic polymorphism in Asian populations, which can lead to delayed action and decreased efficacy of clopidogrel. Ticagrelor, being fast-acting and not requiring metabolic activation, was considered more suitable for deployment of high-metal coverage devices in acute settings. This pharmacological consideration highlights the importance of tailoring antiplatelet regimens to specific patient populations and clinical scenarios. The study findings align with and extend those of previous investigations into flow diversion for blister aneurysms. Rouchaud and colleagues previously demonstrated superior occlusion rates with FDDs compared to other endovascular techniques, without significantly higher complication rates. Similarly, Scerrati and colleagues reported a 76.9% long-term total occlusion rate and 76.6% satisfactory clinical outcome rate for endovascular reconstructive procedures in blister aneurysms. The current study's occlusion rate of 90.5% at follow-up compares favorably with these previous reports, as does the 100% rate of favorable clinical outcomes (mRS 0-2).

The investigators emphasize several key advantages of flow diversion for blister aneurysms. Unlike other endovascular techniques, flow diversion can reconstruct the vessel wall and seal off underlying defects through a process of progressive aneurysm thrombosis and endothelial proliferation along the implanted stents. This is particularly important for blister aneurysms, which are often located near critical perforating branches such as the anterior choroidal or posterior communicating arteries. The gradual nature of aneurysm occlusion following flow diversion, with immediate reduction in shear forces and inflow jets followed by progressive thrombosis over weeks to months, appears well-suited to the pathophysiology of these lesions. The study also contributes to the ongoing debate regarding the timing of flow diversion in the acute setting of aneurysmal rupture. The investigators note that recent studies have found the overall complication rate to be unaffected by the timing of flow diversion, and their results support the safety and efficacy of early intervention (within 72 hours of rupture). This is an important finding given the historical concerns about deploying flow diverters in the acute setting, particularly regarding the necessity of dual antiplatelet therapy and its potential to exacerbate hemorrhagic complications. The study does acknowledge several limitations, including its retrospective design, reliance on a single operator, and absence of a control group. These factors limit the generalizability of the findings and preclude definitive conclusions about the superiority of flow diversion over other treatment modalities for ruptured blister aneurysms.

This study raises several important questions for the neurovascular community. Could early flow diversion with appropriate antiplatelet management become the standard of care for ruptured blister aneurysms, particularly in centers with high endovascular expertise? How might the selection of antiplatelet agents be further optimized based on patient genetics, particularly in populations with known polymorphisms affecting drug metabolism? What is the optimal timing of intervention, and does the window for "early" treatment extend beyond 72 hours in selected cases? Would adjunctive techniques such as coiling provide additional benefit in certain anatomical configurations, or does the simplicity of pure flow diversion offer advantages in terms of procedural risk? Future research directions should include larger, prospective studies with control groups receiving alternative treatments, detailed analysis of antiplatelet regimens and their relationship to outcomes, and longer-term follow-up to assess the durability of aneurysm occlusion and device-related complications. The findings from this single-center experience suggest that early endovascular flow diversion represents a safe, effective, vessel-preserving option for the treatment of ruptured intracranial blister aneurysms when performed by experienced operators with appropriate patient selection and perioperative management. By interfering with the pulsatile flow into the aneurysm, flow-diverting stents appear to facilitate stasis, thrombosis, and eventual aneurysm obliteration while reconstructing the parent artery, potentially offering advantages over both surgical approaches and other endovascular techniques in this challenging patient population.

Summary

A retrospective study from Gleneagles Hospital in Mumbai, India, has demonstrated that early flow diversion—performed within 72 hours of subarachnoid hemorrhage—represents a promising vessel-preserving approach for managing ruptured intracranial blister aneurysms. These rare, fragile lesions constitute less than 2% of all intracranial aneurysms but carry disproportionately high risks of rupture and complications. The study followed 21 patients treated between February 2017 and December 2022, predominantly with lower-grade hemorrhages and atherosclerotic comorbidities. Investigators employed various flow diverter devices without adjunctive coiling, alongside aggressive antiplatelet therapy using ticagrelor and aspirin rather than clopidogrel, citing genetic polymorphisms affecting drug metabolism in Asian populations. Results showed immediate contrast stasis in 85.7% of cases, complete aneurysm obliteration in 90.5% at six-month follow-up, and 100% favorable clinical outcomes with no perioperative mortality, rebleeding, or major complications. The findings suggest that flow diversion facilitates gradual aneurysm thrombosis while reconstructing the parent artery through endothelial proliferation, offering potential advantages over surgical and other endovascular approaches. The study's limitations include its retrospective design, single-operator experience, and absence of a control group, indicating the need for larger prospective trials to establish optimal timing, antiplatelet protocols, and comparative effectiveness against alternative treatments for this challenging vascular pathology.